Teva Passes Its Check-Up - WSJ
Teva Pharmaceutical's U.S. Unit Indicted on Price-Fixing Charges - WSJ
Teva's Benign Opioid Settlement Isn't in the Bag Yet - WSJ
Teva Settles Foreign Corruption Probe for $519 Million - WSJ
Teva Agrees to Settle Opioid Lawsuits for as Much as $4.25 Billion - WSJ
TEVA Pharmaceutical Industries Limited Visits the NYSE - YouTube
Teva Faces U.S. Criminal Probe on Opioid-Related Distribution, Report Says | Ctech
WSJ markets desk names new night editor - Talking Biz News
Teva and Other Generic Drugmakers Inflated Prices Up to 1,000%, State Prosecutors Say - The New York Times
Mylan sees opportunity in rival Teva's weakness - MarketWatch
Teva Pharmaceutical to Replace CEO Kare Schultz - WSJ
Teva Pharmaceutical CEO Schultz stepping down in November 2023 - WSJ (TEVA) | Seeking Alpha
Teva Agrees to Settle Opioid Lawsuits for as Much as $4.25 Billion - WSJ
What To Do After TEVA Stock Falls Below $10 Again (NYSE:TEVA) | Seeking Alpha
Teva Pharmaceutical to Cut 14,000 Jobs - WSJ
Running out of time and money, CEO to prioritize getting Teva out of the hole | The Times of Israel
Teva Pharmaceuticals to Cut 25% of Jobs in Huge Reshaping - The New York Times
Teva Pharmaceutical's Sales Slump 18% - WSJ
Teva offers to buy Mylan in $40 billion deal | The Times of Israel
Teva Pharmaceutical Is in Recovery - WSJ
Why Teva Pharmaceuticals Stock Has Two A-Products In The Bag (NYSE:TEVA) | Seeking Alpha
Teva Tries to Put an End to the Opioid Wars - WSJ
Teva Pharmaceutical's U.S. Unit Indicted on Price-Fixing Charges - WSJ
Suffering from missteps, drugmaker Teva struggles to heal own ills | The Times of Israel
J&J, Teva offer a whopping $48B combined to wrap opioid suits, but not all plaintiffs are on board | Fierce Pharma
